Univariate Cox proportional hazard analysis identified prior taxane therapy, metastatic sites count, LDH, and NLR as pre-treatment prognostic markers of PFS in HER2-positive ABC patients commencing first-line pertuzumab, trastuzumab, and docetaxel (P < 0.05; Supplementary Table 2). This evidence concerns the gene ERBB2 and aneurysmal bone cyst.